West Virginia Code § 30-5-12c

Substitution of biological product: Definitions; selection of
Open in Lexace · Ask the AI about this section
interchangeable biological products; exceptions; records; labels; manufacturing
standards; emergency rules; complaints; and immunity.
(a) As used in this section:
"Biological product" means the same as that term is defined in 42 U.S.C.§ 262.
"Brand name" means the proprietary or trade name selected by the manufacturer and
placed upon a drug or drug product, its container, label, or wrapuping at the time of
packaging.
"Interchangeable biological product" means a biological product that the federal Food and
Drug Administration has: a
(1) Licensed and determined meets the standards for interchangeability pursuant to 42
U.S.C § 262(k)(4); or
(2) Determined is therapeutically equivalent as set forth in the latest edition of or
supplement to the federal Food and Drug Administration's Approved Drug Products with
Therapeutic Equivalence Evaluations.
"Proper name" means the noneproprietary name of a biological product.
"Substitute" means to dLispense without the prescriber's express authorization an
interchangeable biological product in the place of the drug ordered or prescribed.
(b) Except as limited by subsection (c) and unless instructed otherwise by the patient, a
pharmacist who receives a prescription for a specific biological product shall select a less
expensive interchangeable biological product unless in the exercise of his or her professional
judgWment the pharmacist believes that the less expensive drug is not suitable for the
particular patient. The pharmacist shall provide notice to the patient or the patient's
designee regarding the selection of a less expensive interchangeable biological product.
(c) If, in the professional opinion of the prescriber, it is medically necessary that an
equivalent drug product or interchangeable biological product not be selected, the
prescriber may so indicate by certifying that the specific brand-name drug product
prescribed, or the specific brand-name biological product prescribed, is medically necessary
for that particular patient. In the case of a prescription transmitted orally, the prescriber
must expressly indicate to the pharmacist that the specific brand-name drug product
prescribed, or the specific biological product prescribed is medically necessary.
(d) (1) Within five business days following the dispensing of a biological product, the
dispensing pharmacist or the pharmacist's designee shall communicate the specific product
provided to the patient, including the name of the product and the manufacturer, to the
prescriber through any of the following electronic records systems:
(A) An interoperable electronic medical records system;
(B) An electronic prescribing technology;
(C) A pharmacy benefit management system; or
(D) A pharmacy record.
(2) Communication through an electronic records system as described in §30-5-12c(d)(1) of
this code is presumed to provide notice to the prescriber.
(3) If the pharmacist is unable to communicate pursuant to atn electronic records system the
pharmacist shall communicate to the prescriber which biological product was dispensed to
the patient using facsimile, telephone, electronic transmission, or other prevailing means.
(4) Communication is not required under this subsection when:
(A) There is no Federal Food and Drug Administration approved interchangeable biological
product for the product prescribed; or
(B) A refill prescription is not changed from the product dispensed on the prior filling of the
prescription.
(e) The pharmacist shall maintain a record of the biological product dispensed for at least
two years. Such record shall include the manufacturer and proper name of the
interchangeable biological product selected.
(f) All biological products shall be labeled in accordance with the instructions of the
practitioner.
(g) Unless the practitioner directs otherwise, the prescription label on all biological products
dispensed by the pharmacist shall indicate the proper name using abbreviations, if
necessary, and either the name of the manufacturer or packager, whichever is applicable, in
the pharmacist's discretion. The same notation will be made on the original prescription
retained by the pharmacist.
(h) A pharmacist may not dispense a product under the provisions of this section unless the
manufacturer has shown that the biological product has been manufactured with the
following minimum good manufacturing standards and practices by:
(1) Labeling products with the name of the original manufacturer and control number;
(2) Maintaining quality control standards equal to or greater than those of the United States
Food and Drug Administration;
(3) Marking products with identification code or monogram; and
(4) Labeling products with an expiration date.
(i) The West Virginia Board of Pharmacy shall promulgate emergency rules pursuant to the
provisions of §29A-3-15 of this code setting standards for substituted interchangeable
biological products, obtaining compliance with the provisions of this section, and enforcing
the provisions of this section.
(j) Any person shall have the right to file a complaint with the West Virginia Board of
Pharmacy regarding any violation of the provisions of this articleu. Such complaints shall be
investigated by the Board of Pharmacy.
(k) No pharmacist or pharmacy complying with the provisions of this section shall be liable
in any way for the dispensing of an interchangeable biaological product substituted under the
provisions of this section, unless the interchangeable biological product was incorrectly
substituted. l
(l) In no event where the pharmacist substitutes an interchangeable biological product under
the provisions of this section shall the presicribing physician be liable in any action for loss,
damage, injury, or death of any person occasioned by or arising from, the use of the
substitute biological product unless the original biological product was incorrectly
prescribed.
(m) Failure of a practitioner to specify that a specific brand name is necessary for a
particular patient shall not constitute evidence of negligence unless the practitioner had
reasonable cause to believe that the health of the patient required the use of a certain
product and no other .

‹ Prev All West Virginia sections Next ›


Lexace provides legal information, not legal advice, and no attorney–client relationship is created. Statute text is provided for general information and may not reflect the most recent amendments; verify against the official state code.